Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Uterine Diseases

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    611 result(s) found for: Uterine Diseases. Displaying page 7 of 31.
    «« First « Previous 3  4  5  6  7  8  9  10  11  Next» Last»»
    EudraCT Number: 2021-006543-10 Sponsor Protocol Number: XB002-101 Start Date*: 2023-03-27
    Sponsor Name:Exelixis, Inc.
    Full Title: A dose-escalation and expansion study of the safety and pharmacokinetics of XB002 as single-agent and combination therapy in subjects with inoperable locally advanced or metastatic solid tumors
    Medical condition: Advanced solid tumors for whom life-prolonging therapies do not exist or available therapies are intolerable or no longer effective. Single-agent XB002 will be evaluated up to 10 tumor types, and c...
    Disease: Version SOC Term Classification Code Term Level
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10083234 Hormone receptor positive breast cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10064467 Urothelial carcinoma LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008229 Cervical cancer LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041823 Squamous cell carcinoma PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033604 Pancreatic cancer LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10030151 Oesophageal cancer LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10084066 Triple negative breast cancer metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-005683-41 Sponsor Protocol Number: RIOTB2015 Start Date*: 2016-03-16
    Sponsor Name:Sven O. Skouby, Professor, MD, DMSc. Unit of reproductive Medicine, Herlev/Gentofte Hospital
    Full Title: REDUCING THE IMPACT OF OVARIAN STIMULATION - THE RIOT PROJECT RIOT STUDY B: MAPPING THE ENDOCRINE DETERMINANTS OF OVARIAN STIMULATION TO OPTIMIZE OUTCOMES IN FRESH EMBRYO TRANSFER CYCLES ...
    Medical condition: Infertility
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004872 10016401 Female infertility of other specified origin LLT
    20.0 100000004872 10025511 Male infertility, unspecified LLT
    20.0 100000004872 10016403 Female infertility of tubal origin LLT
    Population Age: Adults Gender: Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-005682-24 Sponsor Protocol Number: RIOTA2015 Start Date*: 2016-03-16
    Sponsor Name:Sven Olaf Skouby, Professor, MD, DMSc. Unit of Reproductive Medicine, Herlev/Gentofte Hospital
    Full Title: REDUCING THE IMPACT OF OVARIAN STIMULATION - THE RIOT PROJECT STUDY RIOT A: THE ROLE OF AROMATASE INHIBITOR IN REDUCING THE DETRIMENTAL EFFECTS OF OVARIAN STIMULATION TO OPTIMIZE OUTCOMES IN FRESH...
    Medical condition: Infertility
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004872 10016401 Female infertility of other specified origin LLT
    20.0 100000004872 10025511 Male infertility, unspecified LLT
    20.0 100000004872 10016403 Female infertility of tubal origin LLT
    Population Age: Adults Gender: Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-004445-26 Sponsor Protocol Number: A65870 Start Date*: 2015-03-27
    Sponsor Name:World Health Organization
    Full Title: A phase III, randomized, double-blind, active, controlled, multinational, multicentre, non-inferiority trial using Carbetocin room temperature stable (RTS) for the prevention of postpartum haemorr...
    Medical condition: Postpartum haemorrhage
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004868 10005128 Bleeding postpartum LLT
    Population Age: Adolescents, Under 18, Adults Gender: Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-005420-42 Sponsor Protocol Number: S55983 Start Date*: 2014-02-06
    Sponsor Name:University Hospital Leuven
    Full Title: Is postoperative IUI better than expectant management in infertile endometriosis patients with good prognosis based on EFI score?
    Medical condition: (Sub)Fertility in endometriosis after laparoscopic removal of the endometriosos lesions: an RCT comparing intra-uterine insemination with expectant management
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004872 10042391 Subfertility LLT
    16.1 100000004872 10014789 Endometriosis, site unspecified LLT
    Population Age: Adults Gender: Female
    Trial protocol: BE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-002777-35 Sponsor Protocol Number: 16I-Prg06 Start Date*: 2017-01-18
    Sponsor Name:IBSA INSTITUT BIOCHIMIQUE SA
    Full Title: Prospective, double-blind, randomised, placebo controlled, phase III clinical study assessing the efficacy of natural progesterone 25 mg/bid administered subcutaneously in the maintenance of early ...
    Medical condition: Threatened abortion
    Disease: Version SOC Term Classification Code Term Level
    20.1 10036585 - Pregnancy, puerperium and perinatal conditions 10000242 Abortion threatened PT
    20.0 10022891 - Investigations 10063273 Progesterone normal PT
    20.0 10022891 - Investigations 10063291 Progesterone PT
    20.0 10022891 - Investigations 10063291 Progesterone PT
    Population Age: Gender: Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-001830-32 Sponsor Protocol Number: RC31/17/0448 Start Date*: 2019-12-18
    Sponsor Name:University Hospital Toulouse
    Full Title: Phase III Trial to assess impact of ultra-long versus long down-regulation protocol on IVF/ICSI outcomes in infertile women presenting with adenomyosis.
    Medical condition: Infertilty in women with adenomyosis.
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: FR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-002247-23 Sponsor Protocol Number: MITOCERV4 Start Date*: 2020-01-29
    Sponsor Name:FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE
    Full Title: Single arm phase II study on Pembrolizumab in preneoplastic high grade HPV-related vulvar and cervical lesions
    Medical condition: Patients with pre neoplastic high grade HPV-related vulvar and cervical lesions
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038604 - Reproductive system and breast disorders 10054932 Vulvar dysplasia PT
    20.0 10038604 - Reproductive system and breast disorders 10008263 Cervical dysplasia PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-004690-14 Sponsor Protocol Number: NA Start Date*: 2021-01-12
    Sponsor Name:FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE
    Full Title: RECHALLENGE WITH PEGYLATED LIPOSOMAL DOXORUBICIN ADDED TO TRABECTEDIN IN RECURRENT OVARIAN CANCER: A MULTICENTER, PROSPECTIVE TRIAL (REPRAB study – MITO 36)
    Medical condition: Ovarian cancer
    Disease: Version SOC Term Classification Code Term Level
    22.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10026311 Malignant neoplasm of ovary and other uterine adnexa LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061535 Ovarian neoplasm PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061344 Peritoneal neoplasm PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-001434-29 Sponsor Protocol Number: VX-EC-2-2013 Start Date*: 2015-01-13
    Sponsor Name:AS Kevelt
    Full Title: A Phase II Study of Sodium Cridanimod in Conjunction with Progestin Therapy in Patients with Progesterone Receptor Negative Recurrent or Persistent Endometrial Carcinoma.
    Medical condition: PrR negative papillary serous adenocarcinoma, endometroid type of endometrial carcinoma
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10014743 Endometrial carcinoma LLT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10014747 Endometrial carcinoma recurrent LLT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033700 Papillary serous endometrial carcinoma PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: CZ (Completed) SK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-004364-11 Sponsor Protocol Number: 69HCL15_0321 Start Date*: 2016-03-07
    Sponsor Name:Hospices Civils de Lyon
    Full Title: ENDOLA A PHASE I/II TRIAL TO ASSESS THE SAFETY AND EFFICACY OF METRONOMIC CYCLOPHOSPHAMIDE, METFORMIN AND OLAPARIB IN RECURRENT ADVANCED/METASTATIC ENDOMETRIAL CANCER PATIENTS
    Medical condition: - Patients with histologically and/or cytologically documented endometrial carcinoma (type I or type II), recurrent after platinum-based chemotherapy
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10014736 Endometrial cancer recurrent PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-001732-38 Sponsor Protocol Number: 1502 Start Date*: 2015-09-14
    Sponsor Name:CENTRE OSCAR LAMBRET
    Full Title: EVALUATION OF SENTINEL NODE (SN) POLICY IN EARLY STAGE ENDOMETRIAL CARCINOMAS AT INTERMEDIATE AND HIGH RISK OF RECURRENCE: RANDOMIZED STUDY COMPARING SENTINEL NODE POLICY TO CURRENT FRENCH INITIAL ...
    Medical condition: Intermediate-risk endometrioïd carcinomas : IAg3, IB(II)g1-2 High-risk endometrioïd carcinomas : IB-II g3 High-risk non endometrioïd carcinomas : I-II
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10014733 Endometrial cancer PT
    Population Age: Elderly Gender: Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-000915-26 Sponsor Protocol Number: 000295 Start Date*: 2019-05-10
    Sponsor Name:Ferring Pharmaceuticals A/S
    Full Title: A randomised, double-blind, placebo-controlled, proof-of-mechanism phase 2 trial investigating the effect of quinagolide extended-release vaginal ring on reduction of lesions assessed by high-resol...
    Medical condition: Deep infiltrating endometriosis, endometrioma and/or adenomyosis.
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004872 10014787 Endometriosis of uterus LLT
    Population Age: Adults Gender: Female
    Trial protocol: DE (Completed) DK (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-000266-35 Sponsor Protocol Number: CTKI258A2211 Start Date*: 2012-03-21
    Sponsor Name:NOVARTIS FARMA
    Full Title: A phase II, open-label, single-arm, non-randomized, multi-center study to evaluate the efficacy of oral TKI258 as second-line therapy in patients with either FGFR2 mutated or wild-type advanced and...
    Medical condition: Advanced and/or metastatic endometrial carcinoma
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10014736 Endometrial cancer recurrent PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) ES (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-000948-18 Sponsor Protocol Number: VICORYX Start Date*: 2011-08-25
    Sponsor Name:Oryx GmbH & Co. KG
    Full Title: Phase I/IIa study of immunization with a p16INK4a peptide combined with MONTANIDE ISA-51 VG in patients with advanced HPV-associated cancers
    Medical condition: advanced HPV- and p16INK4a-positive cervical, vulvar, vaginal, penile, anal or head and neck cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008230 Cervix neoplasms malignant HLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10002125 Anal canal neoplasms malignant HLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10026339 Malignant neoplasm of penis, part unspecified LLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10046896 Vaginal neoplasms malignant HLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10047750 Vulval neoplasms malignant HLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067821 Head and neck cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-004046-16 Sponsor Protocol Number: IMC-F106C-101 Start Date*: 2020-04-08
    Sponsor Name:Immunocore Ltd.
    Full Title: A Phase 1/2 First-in-Human Study of the Safety and Efficacy of IMC-F106C as a Single Agent and in Combination with Checkpoint Inhibitors in HLA-A*02:01-Positive Participants with Advanced PRAME-Pos...
    Medical condition: HLA-A*02:01-Positive Participants with Advanced PRAME-Positive Cancers. Study IMC-F106C-101 will enroll participants with advanced cancers, including unresectable or metastatic melanoma, ovarian ca...
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025665 Malignant melanoma of skin stage unspecified LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10042863 Synovial sarcoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10064467 Urothelial carcinoma LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10075566 Triple negative breast cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10046769 Uterine carcinoma LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033131 Ovarian carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2021-003871-32 Sponsor Protocol Number: AL3818-US-002 Start Date*: 2021-11-11
    Sponsor Name:ADVENCHEN LABORATORIES, LLC
    Full Title: A Phase 1/2a/3 Evaluation of the Safety and Efficacy of Adding AL3818 (Anlotinib, INN: Catequentinib), a Dual Receptor Tyrosine Kinase Inhibitor, to Standard Platinum-Based Chemotherapy in Subjects...
    Medical condition: Recurrent or metastatic endometrial, ovarian, fallopian tube, primary peritoneal, or cervical carcinoma.
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10014734 Endometrial cancer metastatic PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10014736 Endometrial cancer recurrent PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057529 Ovarian cancer metastatic PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066697 Ovarian cancer recurrent PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Ongoing) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-006574-23 Sponsor Protocol Number: AR101-PREVEnt Start Date*: 2022-08-30
    Sponsor Name:Aytu BioPharma, Inc.
    Full Title: A multicenter, randomized, double-blind, placebo-controlled study of enzastaurin for the prevention of arterial events in patients with vascular Ehlers-Danlos Syndrome (vEDS) confirmed with COL3A1 ...
    Medical condition: vascular Ehlers-Danlos Syndrome (vEDS) confirmed with COL3A1 mutations
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10014316 Ehlers-Danlos syndrome PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: SE (Ongoing) BE (Prematurely Ended) FR (Ongoing) NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-023081-52 Sponsor Protocol Number: ENGOT-EN2-DGCG Start Date*: 2011-01-25
    Sponsor Name:Danish Gynaecological Cancer Group (DGCG)
    Full Title: A phase II Trial of postoperative chemotherapy or no further treatment for patients with node-negative stage I-II intermediate or high risk endometrial cancer.
    Medical condition: Endometrial cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10014738 Endometrial cancer stage I PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10014739 Endometrial cancer stage II PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DK (Completed) SE (Completed) BE (Completed) FI (Completed) AT (Completed) GB (GB - no longer in EU/EEA) ES (Ongoing) DE (Completed) IT (Completed) NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-001175-38 Sponsor Protocol Number: 6520-9170-08 Start Date*: 2012-01-13
    Sponsor Name:MEDICE Arzneimittel Pütter GmbH & CO.KG
    Full Title: A multi-center, randomized, double-blind,phase II trial with intraindividual comparison to assess superiority of Soventol HydroCort 0.5 % Cremogel vs vehicle on lesional skin in patients with mild ...
    Medical condition: manifest atopic dermatitis diagnosed according to Hanifin and Rajka, or seborrheic eczema or stasis dermatitis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 3  4  5  6  7  8  9  10  11  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 15 09:03:07 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA